GUERRINI, FRANCESCA
 Distribuzione geografica
Continente #
NA - Nord America 3.926
EU - Europa 2.276
AS - Asia 1.593
SA - Sud America 273
AF - Africa 111
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 4
Totale 8.201
Nazione #
US - Stati Uniti d'America 3.804
IT - Italia 797
CN - Cina 535
SE - Svezia 483
SG - Singapore 389
HK - Hong Kong 274
GB - Regno Unito 254
BR - Brasile 251
DE - Germania 237
BG - Bulgaria 174
VN - Vietnam 116
TR - Turchia 106
CA - Canada 103
FI - Finlandia 76
RU - Federazione Russa 74
CI - Costa d'Avorio 54
FR - Francia 45
IN - India 39
UA - Ucraina 35
BE - Belgio 33
SN - Senegal 26
JP - Giappone 24
PH - Filippine 23
KR - Corea 19
AU - Australia 18
ES - Italia 13
CH - Svizzera 12
NL - Olanda 12
BD - Bangladesh 11
MX - Messico 9
NG - Nigeria 9
SA - Arabia Saudita 8
UZ - Uzbekistan 8
PK - Pakistan 7
CZ - Repubblica Ceca 6
IQ - Iraq 6
MY - Malesia 5
PL - Polonia 5
VE - Venezuela 5
ZA - Sudafrica 5
AR - Argentina 4
GR - Grecia 4
JO - Giordania 4
KE - Kenya 4
LT - Lituania 4
MA - Marocco 4
TN - Tunisia 4
AT - Austria 3
CO - Colombia 3
EC - Ecuador 3
EG - Egitto 3
EU - Europa 3
UY - Uruguay 3
AE - Emirati Arabi Uniti 2
BM - Bermuda 2
BT - Bhutan 2
DK - Danimarca 2
HN - Honduras 2
HR - Croazia 2
ID - Indonesia 2
IE - Irlanda 2
IR - Iran 2
PS - Palestinian Territory 2
TH - Thailandia 2
TT - Trinidad e Tobago 2
TW - Taiwan 2
AZ - Azerbaigian 1
BB - Barbados 1
BJ - Benin 1
BO - Bolivia 1
BS - Bahamas 1
CL - Cile 1
CR - Costa Rica 1
EE - Estonia 1
ET - Etiopia 1
GE - Georgia 1
IL - Israele 1
KZ - Kazakistan 1
MD - Moldavia 1
OM - Oman 1
PA - Panama 1
PY - Paraguay 1
RO - Romania 1
SR - Suriname 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 8.201
Città #
Serra 388
Ashburn 372
Woodbridge 365
Fairfield 359
Santa Clara 324
Hong Kong 272
Ann Arbor 271
Houston 268
Chandler 261
Seattle 193
Singapore 175
Sofia 170
Beijing 154
Shanghai 149
Wilmington 146
Cambridge 125
New York 107
Milan 97
Boardman 91
Princeton 86
Ottawa 78
London 68
Florence 62
Medford 60
Izmir 59
Lawrence 59
Abidjan 54
Los Angeles 45
Jacksonville 42
Des Moines 41
Munich 38
Dearborn 35
Nanjing 35
Istanbul 30
San Diego 28
Dong Ket 27
Dakar 26
Brussels 23
Lancaster 23
Pisa 23
Bremen 20
Redwood City 20
Rome 20
Frankfurt am Main 19
Nanchang 19
Turku 16
Helsinki 14
Shenyang 13
Alessandria 12
Council Bluffs 12
São Paulo 12
Changsha 11
Düsseldorf 11
Fuzhou 11
Hefei 11
Manila 11
Rio de Janeiro 11
The Dalles 10
Tokyo 10
Duncan 9
Falkenstein 9
Lagos 9
Nuremberg 9
Bern 8
Hebei 8
Jüchen 8
Melbourne 8
Boulder 7
Dallas 7
East Lansing 7
Jiaxing 7
Kunming 7
Norwalk 7
Phoenix 7
Porto Alegre 7
Tashkent 7
Toronto 7
Campinas 6
Cascina 6
Chengdu 6
Falls Church 6
Hangzhou 6
Nürnberg 6
Perth 6
Tianjin 6
Washington 6
Westminster 6
Zhengzhou 6
Amsterdam 5
Charlottetown 5
Chābua 5
Palermo 5
Quanzhou 5
Seocho-gu 5
Amman 4
Ankara 4
Boston 4
Brasília 4
Brooklyn 4
Chicago 4
Totale 5.750
Nome #
The perception of stress in cat owners 266
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen. Leuk Lymphoma 215
Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during Imatinib treatment 190
Arsenic trioxide and ascorbic acid interfere with the BCL2 family genes in patients with myelodysplastic syndromes: an ex-vivo study. 187
Association of the hOCT1/ABCB1 genotype with efficacy and tolerability of imatinib in patients affected by chronic myeloid leukemia 180
Evaluation of the MDR1, ABCG2, Topoisomerases IIalpha and GSTpi gene expression in patients affected by aggressive mantle cell lymphoma treated by the R-Hyper-CVAD regimen 175
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia 173
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 170
Transmembrane Transporters hOCT1 and SLCO1B3 Polymorphisms Could Have a Role in Patients Affected By Chronic Myeloid Leukemia Treated with Nilotinib 164
Polycomb genes are associated with response to imatinib in chronic myeloid leukemia 164
Combined unfavourable polymorphisms ofhOCT1 and ABCG2 are responsible for delayed complete cytogenetic response during imatinib treatment. 161
A PRACTICAL APPROACH TO THERAPEUTIC DRUG MONITORING OF IMATINIB IN PATIENTS AFFECTED BY CHRONIC MYELOID ELEUKEMIA. THE TIKLET PROTOCOL. 160
The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia 159
Reduced circulating B-lymphocytes and altered B-cell compartments in patients suffering from chronic myeloid leukaemia undergoing therapy with Imatinib 158
The combination of rituximab and bendamustine as first-line treatment is highly effective in the eradicating minimal residual disease in follicular lymphoma: An Italian retrospective study 152
MDS: An Integrated Workup for a Correct Diagnosis 151
PLATELET-DERIVED GROWTH FACTOR BETA RECEPTOR (PDGFRB) GENE IS REARRANGED IN A SIGNIFICANT PERCENTAGE OF MYELODYSPLASTIC SYNDROMES WITH NORMAL KARYOTYPE 150
Significant co-expression of WT1 and MDR1 genes in acute myeloid leukemia patients at diagnosis 148
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 148
Synergistic antiproliferative effect of arsenic trioxide combined with bortezomib in HL60 cell line and primary blasts from patients affected by myeloproliferative disorders. 148
TCR REARRANGEMENTS ARE NOT ENOUGH FOR DISTINGUISHING THE CHURG-STRAUSS SYNDROME FROM THE HYPEREOSINOPHILIC SYNDROME 147
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 144
Droplet digital PCR represents a new sensitive method for detecting B-RAFV600E mutation at diagnosis and during the follow-up of patients affected by hairy cell leukemia 139
Comparison of Real-Time PCR and Droplet Digital PCR for the Determination of JAK2V617F Mutation in Ph'-Negative Myeloproliferative Neoplasms 139
Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: The FIL FOLL05 trial 138
Evaluation of BCRP and MDR-1 co-expression by quantitative molecular assessment in AML patients 136
A Novel Digital PCR Assay for MYD88 L265P Mutation Detection in Waldenstrom Macroglobulinemia: Minimal Residual Disease Monitoring and Characterization on Circulating Free DNA 134
Increased values of the circulating PDGFβ sustains the "withdrawal syndrome" after tyrosine kinase inhibitor discontinuation in patients affected by chronic myeloid leukemia 133
Myelodysplastic syndromes: advantages of a combined cytogenetic and molecular diagnostic workup 132
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 131
LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES 131
Molecular detection of GNNK- and GNNK+ c-kit isoforms: a new tool for risk stratification in adult acute myeloid leukaemia 130
WT1 expression levels at diagnosis could predict long-term time-to-progression in adult patients affected by acute myeloid leukaemia and myelodysplastic syndromes 129
Combined FAMD and ANOVA investigation leads to significant association between the hOCT1/ABCB1 diplotype and both efficacy and tolerability in patients affected by chronic myeloid leukemia 127
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EGPA FROM HES 126
Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation 119
Vorinostat interferes with Wnt and NF-kappaB pathways in the M-07e cell line 117
Quantitative molecular evaluation in autotransplant programs for follicular lymphoma: efficacy of in vivo purging by Rituximab 116
Peripheral blood stem cell contamination evaluated by a highly sensitive molecular method fails to predict outcome of autotransplanted multiple myeloma patients 113
Altered Expression of Jak-Stat Pathway as Possible Predictive Marker in Patients Affected by Chronic Myeloid Leukemia Receiving Tyrosin Kinase Inhibitors (TKIS) 113
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 111
Platelet-derived growth factor beta receptor (PDGFRB) gene is rearranged in a significant percentage of myelodysplastic syndromes with normal karyotype 110
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients 110
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 109
The Minimal Residual Disease in Non-Hodgkin's Lymphomas: From the Laboratory to the Clinical Practice 107
The assessment of minimal residual disease versus that of somatic mutations for predicting the outcome of acute myeloid leukemia patients 106
The clinical relevance of the expression of several multidrug-resistant-related genes in patients with primary acute myeloid leukemia 105
Quantitative molecular evaluation of minimal residual disease in patients with chronic lymphocytic leukemia: efficacy of in vivo purging by alemtuzumab (Campath-1H). 102
R-IPSS, RPS14 AND WT1 LEVELS ARE THE BEST PROGNOSTIC FACTORS FOR PATIENTS AFFECTED BY MYELODYSPLASTIC SYNDROMES DURING AZACITIDINE TREATMENT. 102
TCR GAMMA CLONALITY ASSESSED BY NGS DOES NOT HELP TO DISTINGUISH EOSINOPHILOIA IN EGPA FROM HES 102
Conventional Cytogenetics, ACGH, and PCR as Integrated Workup for a Correct Diagnosis of MDS 101
ITF2357 interferes with apoptosis and inflammatory pathways in the HL-60 model: a gene expression study. 100
Myelodysplastic Syndromes: A Multidisciplinary Integrated Diagnostic Work-up for Patients' Risk Stratification 100
FLT3 mutations do not influence MDR-1 gene expression in acute myeloid leukemia 97
The role of molecular monitoring in autotransplantation for non-Hodgkin's lymphoma 91
Sorafenib Induced Complete Cytogenetic and Molecular Response in a Chronic Eosinophilic Leukemia Case with t(12;13) Translocation 90
Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2 86
THE C.480C>G POLYMORPHISM OF HOCT1 TRANSPORTER INFLUENCES IMATINIB CLEARANCE IN PATIENTS AFFECTED BY CHRONIC MYELOID LEUKEMIA 84
TYROSINE KINASE INHIBITORS SIGNIFICANTLY CHANGE THE EXPRESSION OF POLYCOMB GENES IN CHRONIC MYELOID LEUKEMIA 83
Real-Time PCR and Droplet Digital PCR: two techniques for detection of the JAK2(V617F) mutation in Philadelphia-negative chronic myeloproliferative neoplasms 80
Digital droplet PCR is a specific and sensitive tool for detecting IDH2 mutations in acute myeloid leukemia patients 80
Highly sensitive MYD88L265P mutation detection by droplet digital polymerase chain reaction in Waldenström macroglobulinemia 80
molecular evaluation of minimal residual disease in multiple myeloma 72
quantitative molecular detection of IgH rearrangement in multiple myeloma: comparison of two innovative techniques 65
Digital Droplet PCR in Hematologic Malignancies: A New Useful Molecular Tool 40
A new digital droplet PCR method for looking at epigenetics in diffuse large B‐cell lymphomas: The role of BMI1, EZH2, and USP22 genes 35
Totale 8.361
Categoria #
all - tutte 23.893
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 23.893


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202058 0 0 0 0 0 0 0 0 0 0 0 58
2020/2021570 31 40 20 19 38 31 42 44 64 45 54 142
2021/2022859 30 42 13 64 144 117 30 32 70 29 70 218
2022/20231.062 159 210 68 72 86 116 8 85 168 6 79 5
2023/2024691 59 54 97 40 77 120 37 19 9 44 22 113
2024/20252.225 11 75 15 131 258 243 198 134 208 279 217 456
Totale 8.361